首页> 外文期刊>Indian Journal of Pathology and Microbiology >Clinicopathological correlation of cancer stem cell markers Oct-4 and CD133 expression as prognostic factor in malignant lesions of gallbladder: An immunohistochemical study
【24h】

Clinicopathological correlation of cancer stem cell markers Oct-4 and CD133 expression as prognostic factor in malignant lesions of gallbladder: An immunohistochemical study

机译:癌干细胞标志物Oct-4和CD133表达作为胆囊恶性病变预后因素的临床病理相关性:一项免疫组织化学研究

获取原文
           

摘要

Background: Gallbladder cancer (GBC) is the most frequent biliary tract cancer, with high morbidity and poor prognosis, and shows early metastasis and invasiveness. No reliable biomarkers are available for detection of GBC progression. Aim: To investigate the immunohistochemical expression of Oct-4 and CD133 in malignant and nonneoplastic lesions of gallbladder and to analyze the clinical significance of the expressions related to clinicopathological parameters. Settings and Design: This is a prospective case control study, conducted in medical college background. Materials and Methods: A total of 103 cases of gallbladder were grouped into malignant lesions (n = 48) and nonneoplastic lesions (simple epithelial hyperplasia; n = 35 and chronic cholecystitis; n = 20). All tissue samples were evaluated for expression of Oct-4 and CD133 using immunohistochemistry in an effort to elucidate the correlation between their expressions with clinicopathological parameters. Statistical Analysis: The final score was calculated by multiplying the intensity to the percentage of positive cells. The scores ≥2 were considered as positive. Results: Significant positive correlation of higher expression levels of Oct-4 and CD133 were observed in malignant as compared to nonneoplastic lesions of gallbladder (P 0.0001). High expression of Oct-4 and CD133 were significantly associated with tumor grading (Oct-4, P = 0.04; CD133, P = 0.02), staging (Oct-4, P = 0.03; CD133, P = 0.02), and liver metastasis (Oct-4, P = 0.01; CD133, P = 0.007). Significantly reduced survival was observed with high expression of Oct-4 (P = 0.002). No significant correction was observed between CD 133 and survival. Conclusion: This study revealed that high expression level of Oct-4 may provide a new insight for the prognosis of the disease in terms of clinical staging and grade.
机译:背景:胆囊癌(GBC)是最常见的胆道癌,发病率高,预后差,并显示早期转移和浸润性。没有可靠的生物标志物可用于检测GBC进展。目的:探讨Oct-4和CD133在胆囊恶性和非肿瘤性病变中的免疫组织化学表达,并分析其表达与临床病理参数相关的临床意义。设置与设计:这是一项前瞻性病例对照研究,在医学院背景下进行。材料与方法:将103例胆囊癌分为恶性病变(n = 48)和非肿瘤性病变(单纯上皮增生; n = 35和慢性胆囊炎; n = 20)。为了阐明它们的表达与临床病理参数之间的相关性,使用免疫组织化学对所有组织样品的Oct-4和CD133的表达进行了评估。统计分析:通过将强度乘以阳性细胞的百分比来计算最终得分。得分≥2被认为是积极的。结果:与非肿瘤性胆囊病变相比,Oct-4和CD133高表达水平与恶性肿瘤有显着正相关(P <0.0001)。 Oct-4和CD133的高表达与肿瘤分级(Oct-4,P = 0.04; CD133,P = 0.02),分期(Oct-4,P = 0.03; CD133,P = 0.02)和肝转移显着相关(Oct-4,P = 0.01; CD133,P = 0.007)。用Oct-4高表达观察到存活率显着降低(P = 0.002)。在CD 133和存活率之间未观察到明显的校正。结论:这项研究表明,Oct-4的高表达水平可能从临床分期和等级方面为疾病的预后提供新的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号